The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 112.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,500.00
High: 12,586.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Sterling gains as risk sentiment improves

Tue, 24th Nov 2020 11:39

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Adds chart and detail, updates prices)

By Olga Cotaga

LONDON, Nov 24 (Reuters) - Demand for riskier assets on
Tuesday kept sterling close to the two-month high it reached the
day before, with investors also hoping that this week's Brexit
talks will result in a deal.

News on Monday that AstraZeneca's vaccine for the
coronavirus could be around 90% effective boosted sentiment.
British Prime Minister Boris Johnson said on Monday that he
hoped almost all Britons at high risk from COVID would be
vaccinated against the disease by Easter.

England will introduce a new system on Dec. 15 allowing
passengers arriving from high-risk countries to take a COVID-19
test after five days of quarantine and to be released from any
further self-isolation if they test negative.

In addition, the one-month full lockdown in England is due
to end on Dec. 2, and transport secretary Grant Shapps is set to
scrap blanket travel quarantine restrictions by Christmas so
people can travel to high-risk countries to visit relatives.

The November flash purchasing managers index came in better
than expected on Monday, adding to the optimism, although the
number remained below 50, which represents contraction.

Sterling was stronger in early morning trading, but gave
back some of those gains after data showed that British retail
sales have fallen by the most since June during this month's
lockdown across the bulk of the country.

Month-end investment flows have curtailed gains in sterling
and the pound should be trading higher on these developments,
said Marshall Gittler, head of investment research at BDSwiss
Group.

"I think the pound could continue the gains next month,
depending of course on how the Brexit talks go," he said.

The British pound was last up 0.2% at $1.3350,
close to $1.3396, its highest since Sept. 2, reached on Monday.
It was earlier at $1.3380. If it were to rise above $1.3481, the
surge would propel it to nearly a one-year high.

Versus the euro, the moves in the pound were more contained,
with the British currency trading down 0.1% versus the common
currency at 88.97 pence.

London and Brussels this week continue their negotiations to
agree a deal on their future trading relationship, though time
is now running very short as Britain's post-Brexit transition
period ends in fewer than six weeks.

Without an agreement, Britain would revert to trading with
the EU on World Trade Organisation rules, an outcome both sides
believe would disrupt their economies.

Most investors believe a deal will be clinched, even if it
is a bare-bones one that leaves some trade discussions for
later.

Traders were buying more put sterling options - as seen in
the one-month risk reversals levels - which usually means more
people are expecting the pound to fall than those expecting it
to rise in the next few weeks. The levels are not as low as they
were in mid-September, though.

(Reporting by Olga Cotaga, editing by Larry King)

More News
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more
11 Sep 2023 21:54

AstraZeneca says Fasenra therapy meets primary endpoint at trial

(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis.

Read more
11 Sep 2023 10:17

UPDATE: AstraZeneca has good results from three cancer drugs in trials

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
11 Sep 2023 06:59

AstraZeneca says Imfinzi and Tagrisso combinations show good results

(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer.

Read more
6 Sep 2023 09:36

AstraZeneca working with FDA on Ultomiris risk evaluation changes

(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.